Objective: The coincidence of autism with epilepsy is 27% in those individuals with intellectual disability.
glutamate receptors with the underling cytoskeleton, in particular F-actin elements. 8, 9 Loss of SHANK3 in multiple model systems, cultured neurons to mice, has demonstrated synaptic dysfunction. [10] [11] [12] [13] As such, SHANK3 is a critical protein for biogenesis and maintenance of synapses as well as synapse function.
Epilepsy has been reported in individuals found to have 22q13 deletions including SHANK3, with a prevalence ranging from 17 to 70% in multiple case series ( Table 1) . Most of these studies, however, have provided limited information about the semiology, frequency, or severity of seizures in this population, and they have not provided information about the spectrum or frequency of electroencephalography (EEG) abnormalities of these patients. Herein we present a detailed report of the spectrum of seizures and electroencephalographic findings in individuals with SHANK3 loss-of-function mutations. We find significant heterogeneity in seizure types and frequency in our cohort. Furthermore, we identify a wide spectrum of EEG abnormalities in our subjects that are present in both individuals diagnosed with epilepsy and those without.
Patients and Methods

Ethics
This study was approved by the Baylor College of Medicine Institutional Review Board. All participants or their guardians provided written informed consent to participate in this study.
Patient selection and evaluation
We retrospectively collected data from a single center (Texas Children's Hospital) through the electronic medical record. Information about the seizure characteristics of 24 individuals (10 male and 14 female) with either a chromosomal deletion encompassing chromosome 22q13 including SHANK3, point mutation, indel, or microduplication of SHANK3 predicted to result in a loss-of-function mutation were analyzed. Data regarding the onset of first clinical seizure, seizure frequency, duration, semiology, response to pharmaceutical and nonpharmaceutical therapies, and neuroimaging abnormalities were collected and analyzed.
Electroencephalography interpretation
EEG studies were obtained at a single site with review by a board certified neurophysiologist. The video-EEG recordings were obtained using the Nicolet video-EEG system (Natus Medical, Inc.), whereas patients were awake, drowsy, and, when possible, asleep with a 21-channel EEG acquisition system using silver-chloride surface electrodes. The EEG data were reviewed in both bipolar and referential montages. 23 
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Results
Clinical findings
We retrospectively evaluated 24 subjects with SHANK3 mutations including 20 individuals with chromosomal deletions of 22q13.33 including SHANK3 and 4 individuals with point mutations identified by whole exome sequencing resulting in either frameshift or missplicing of the SHANK3 coding frame ( Table 2 ). We found that 11 of 24 subjects had a history of at least one lifetime seizure (46%), including 2 of the 4 individuals with point mutations. The spectrum of seizure semiologies varied significantly from atypical absence seizures (90%) being the most common seizure type to tonic (54%), atonic (18%), tonic-clonic (9%), and myoclonic (9%) in those individuals with a history of clinical seizure. Six (54%) of the 11 subjects with a history of seizure had more than one seizure type, and two patients from this cohort (8%) were diagnosed with Lennox-Gastaut syndrome based on the combination of multiple seizure types (including tonic seizures), intractability of their seizures, and characteristic EEG finding of generalized bursts of 1.5-2 Hz spike and slow wave activity. Five (20%) of our 24 subjects had a history of status epilepticus requiring emergency intravenous medication for cessation of seizure activity. The onset of first seizure ranged from 14 months to 14 years, with a mean age of onset of 5.2 years AE 3.9 (standard deviation, SD). The frequency of seizures similarly varied from a single lifetime seizure to hundreds of seizures per day ( Table 2) .
Electrographic findings
EEG abnormalities were identified in 14 (67%) of 21 subjects for which EEG data were available. The spectrum of EEG abnormalities was wide, from slowing or absence of the occipital dominant rhythm (42%) to focal spike and slow wave discharges (38%) to generalized spike and slow wave discharges (19%) (Fig. 1) . Several patients had combinations of the above-mentioned abnormalities. Of the 21 patients with EEG data available, 5 had an abnormal EEG (either slow occipital dominant rhythm or focal spike and slow wave activity or both) but no history of clinical seizure (23%).
Most individuals with multiple seizure types had an abnormally slow occipital dominant rhythm (83%), whereas the majority of individuals with a single seizure type were found to have an age-appropriate occipital dominant rhythm (60%). Similarly, both individuals with high seizure burden of hundreds of seizure per day prior to anticonvulsant medication were found to have a significantly slowed occipital dominant rhythm. However, it should be noted that 3 (30%) of the 10 individuals for whom we have EEG data and without a history of seizure had abnormally slow occipital dominant rhythm.
Neuroimaging
Of our 24 subjects, 21 had an anatomic brain magnetic resonance imaging (MRI) study available for review (88%). The abnormalities identified varied greatly between individuals (Fig. 2) . The most common abnormalities were dysmorphisms of the corpus callosum (29%) and T 2 hyperintensities of the deep white matter (24%). Anatomic brain abnormalities were detected in both individuals with history of seizures (33%) and without (38%).
Treatments
The type and number of anticonvulsant medications prescribed varied greatly among subjects. The most commonly prescribed anticonvulsant was lamotrigine (17%) followed by levetiracetam and topiramate (12% each) and then several others in <10% of this population (rufinamide, zonisamide, perampanel, felbamate, valproate, carbamazepine, oxcarbazepine, lacosamide, phenytoin, methsuximide, chlorazepate, lorazepam, and phenobarbital). Although underpowered to evaluate for efficacy in this study, no medication was clearly superior for seizure prophylaxis. There was a trend for those with one seizure type to respond to fewer medications than those with multiple seizure semiologies. All individuals with only one semiology (six) were maintained on <2 anticonvulsant medications, whereas three of five individuals with multiple seizure types required two or more maintenance anticonvulsant medications (p = 0.06, Fisher's exact test). Two individuals were found to have pharmacoresistant epilepsy and had implantation of vagus nerve stimulators with mild improvement in seizure frequency (<50% reduction in seizures).
Longitudinal outcomes
Of the 11 patients described here with SHANK3 loss-offunction mutation and a history of seizure, 5 (no. 1, 2, 4, 11, and 13) were evaluated at least twice in clinic.
Patient 2 developed epilepsy at 8 years of age, with the first seizure being generalized tonic-clonic and lasting >5 min, thus requiring intravenous medication. Seizures evolved to include atonic and myoclonic seizures at 9 years of age and tonic seizures by 10 years of age, at which time he was diagnosed with Lennox-Gastaut syndrome. Medication history included initiation of 14 different anticonvulsants in multiple combinations. The ketogenic diet was also attempted, initially with reduction of seizure burden by 90%, but followed by return of multiple daily seizures leading to its discontinuation. A vagus nerve stimulator was also implanted at 10 years of age with initially >50% reduction in seizure burden following escalation of therapy, but subsequent increasing seizure burden. Following multiple injuries from atonic seizures despite use of a protective helmet, corpus callosotomy was performed at 15 years of age with significant reduction in frequency and severity of atonic seizures for >2 years. Initial neuroimaging was normal, but developed into T 2 hyperintensity of the left hippocampus suggestive of mesial temporal sclerosis. Patient 4 developed epilepsy at 2 years of age. The initial seizure type was atypical absence seizure, and this remains her only semiology. Initial treatment with lamotrigine was not efficacious, and she was transitioned to zonisamide therapy with <1 seizure per month.
Patient 1 had her first seizure at 14 months of age, which was an episode of febrile status epilepticus. This initial event was characterized by a tonic seizure with decreased responsiveness. This was followed by multiple daily atypical absence seizures at which point she was initiated on levetiracetam therapy, which reduced her seizure burden from daily to <1 per month.
Patient 11 had a history of two lifetime seizures both occurring with fever. The first was at 1 year of age. Both lasted <1 min. This patient was never placed on anticonvulsant medication.
Patient 13's only seizure occurred at 6 years of age and was associated with illness. The seizure lasted for approximately 30 min, requiring intravenous medication. She has never required daily anticonvulsant medication.
Discussion
Herein we present extensive data of seizure characterization and EEG abnormalities in individuals with SHANK3 mutations. SHANK3 haploinsufficiency is believed to be the etiology of the cognitive abnormalities in individuals with Phelan-McDermid syndrome (PMS) due to a similar phenotype in an individual with a balanced translocation disrupting SHANK3 and multiple studies that have identified individuals with point mutations, indels, or small duplications involving the SHANK3 gene who have autistic traits and intellectual disability similar to those of individuals with chromosomal deletions encompassing SHANK3. 11, 14, 15 Epilepsy is present in a substantial number of individuals with PMS with a pooled prevalence of 32% in unique studies available from the literature including this one. It is unclear whether mutations in SHANK3 underlie the increased propensity for epilepsy in PMS. In our cohort, we identified four individuals by exome sequencing with variants in SHANK3 predicted to be deleterious. Of these, two developed epilepsy. Furthermore, the largest study to date of 22q13 deletions found no significant differences in deletion size in those with epilepsy and those without. 2 These data provide preliminary evidence that loss-of-function mutations in SHANK3 can increase the likelihood to develop epilepsy; however, confirmation will require larger cohorts of individuals with indels and nonsense mutations in SHANK3.
One previous study investigating the seizure types associated with PMS suggested that epilepsy associated with this disorder is mild and easily pharmacologically controlled. 16 We find in our cohort that some individuals with SHANK3 deletions do have infrequent and easily managed epilepsy, but we also identified individuals with intractable seizures including LGS, which has been previously reported in one adult with a chromosome 22q13 deletion including the SHANK3 gene. 17 It is unclear exactly what distinguishes those individuals who will have a single seizure semiology and infrequent seizures from those who have multiple seizure types. There was no significant difference in deletion size, neuroimaging finding, or other clinical characteristic ( Table 2 ). The only parameter that trended with multiple seizure types was slow or absent occipital dominant rhythm (five of six) in individuals with multiple seizure types versus those with a single seizure type (two of five). Together, these data demonstrate that medical practitioners must educate families caring for individuals with SHANK3 loss-of-function mutations that epilepsy can become pharmacoresistent and intractable.
Why haploinsufficiency of SHANK3 would predispose to epilepsy is unclear. Multiple lines of mice with loss-of-function mutations in SHANK3 have been reported to date. 10, 12, 13 Only one (Shank3 alpha/beta isoform knockout) has been reported to have spontaneous seizures, although these seizures were not characterized in detail. 10 Excitatory neurons differentiated from patient derived induced pluripotent stem cells (iPSCs) with SHANK3 deletions have been reported. 18 These neurons display multiple molecular and neurophysiologic abnormalities. It is notable that they have increased input resistance compared to control neurons. This indicates a tendency to increased excitability potentially underlying the elevated prevalence of epilepsy in individuals with SHANK3 mutations compared with the general population. Recently a mechanism for the increased input resistance of stem cell-derived neurons has been proposed. 19 Utilizing neurons derived from human embryonic stem cells with a targeted mutation of SHANK3, impairment of I h currents was identified due to reduced expression of subunits of hyperpolarization-activated cyclic nucleotide-gated (HCN) channels. Moreover, mutations in HCN channels have been clinically associated with epilepsy. 20 Intriguingly, although the seizures were polymorphic in individuals with HCN1 mutations, all patients reported in this study were diagnosed with atypical absence seizures. Together, these data suggest a mechanism by which haploinsufficiency of SHANK3 might predispose to epilepsy and why there is a wide spectrum of seizure semiologies, with atypical absence being the most common type of seizure in patients with SHANK3 haploinsufficiency.
There are no consistent neuroimaging abnormalities that are likely to predispose to seizures. In particular, there is no evidence in our population, or from previous reports, of migrational abnormalities that are likely causative of the seizures. In our cohort, we found neuroimaging abnormalities as frequently in subjects with a history of seizures as those without. What is less clear is whether individuals with SHANK3 mutations have microscopic neuroanatomic abnormalities or abnormalities in connectivity that might be responsible for both the cognitive dysfunction and propensity for epilepsy. Determining this will require more advanced neuroimaging techniques such as diffusion tensor imaging or functional MRI to determine.
Summary
Loss-of-function mutations in SHANK3, either through chromosomal deletion or point mutation, predispose to seizures and EEG abnormalities. Atypical absence seizures are the most common seizures in individuals with SHANK3 mutations; however, there is a wide spectrum of seizure types. No specific EEG abnormality is present in our cohort, and abnormalities were seen in both individuals with a history of seizures and those without. Neuroimaging in our cohort did not identify a specific abnormality associated with seizures. No pharmacologic therapies were clearly superior for treating patients in our cohort. Individuals with loss-of-function mutations in SHANK3 should be monitored for seizure activity.
